Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Enanta Pharmaceuticals Inc

ENTA
Current price
10 USD +0.23 USD (+2.35%)
Last closed 9.76 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 205 534 864 USD
Yield for 12 month -76.78 %
Week
Month
Year
ENTA
21.11.2021 - 28.11.2021

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472

Analytics

WallStreet Target Price

23.88 USD

P/E ratio

Dividend Yield

Current Year

+79 204 000 USD

Last Year

+86 160 000 USD

Current Quarter

+18 932 000 USD

Last Quarter

+18 892 000 USD

Current Year

+79 204 000 USD

Last Year

+86 160 000 USD

Current Quarter

+18 932 000 USD

Last Quarter

+18 892 000 USD

Key Figures ENTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -134 836 000 USD
Operating Margin TTM -163.9 %
PE Ratio
Return On Assets TTM -20.47 %
PEG Ratio
Return On Equity TTM -49.74 %
Wall Street Target Price 23.88 USD
Revenue TTM 79 204 000 USD
Book Value 10.29 USD
Revenue Per Share TTM 3.78 USD
Dividend Share
Quarterly Revenue Growth YOY -6.8 %
Dividend Yield
Gross Profit TTM 86 160 000 USD
Earnings Share -6.38 USD
Diluted Eps TTM -6.38 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -66.2 %
Profit Margin -168.95 %

Dividend Analytics ENTA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ENTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ENTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 8.1396
Price Sales TTM 2.595
Enterprise Value EBITDA 1.1165
Price Book MRQ 0.9483

Financials ENTA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ENTA

For 52 weeks

8.08 USD 62.06 USD
50 Day MA 9.56 USD
Shares Short Prior Month 1 336 144
200 Day MA 23.21 USD
Short Ratio 5.05
Shares Short 1 505 578
Short Percent 9.22 %